T(6;11) translocation renal cell carcinoma is one of the more unusual members of the kidney cancer family. It arises when a piece of chromosome 6 carrying the TFEB gene is swapped with a piece of chromosome 11 carrying the Alpha gene, producing an abnormal fusion transcript called Alpha-TFEB. The fusion gene drives abnormally high levels of TFEB activity inside tumor cells, and clinicians have long observed that this subtype, first described in 2001 as a distinctive pediatric renal neoplasm, can behave aggressively in some patients while remaining indolent in others. Because the tumor is rare, accounting for only a small fraction of renal cell carcinomas, large clinical trials have been difficult to organize, and the molecular details of how the fusion gene actually promotes malignancy have remained only partially mapped. The new study was designed to fill in one crucial stretch of that map.

The research team, led by He-Qin Zhan of the Department of Pathology at Anhui Medical University, with Hai-Yan Ni, Xiao-Xun Zhang and Xin-Ran Wang as co-first authors, built on cell lines their group had established in earlier work. These lines, designated HK-2-TFEB and Caki-2-TFEB, carry stable expression of the Alpha-TFEB fusion gene and serve as laboratory models of the translocation cancer. Western blotting confirmed that TFEB protein was abundant in both engineered lines compared with matched control cells. When the investigators measured RNA levels, they found that LINC00612, a long intergenic non-protein coding RNA, was significantly elevated in the fusion-positive cells, while miR-31-5p was reduced and CTNNB1, the gene encoding beta-catenin, was increased. That reciprocal pattern, high lncRNA, low microRNA, high target gene, is the classic signature of a competing endogenous RNA, or ceRNA, network.

The ceRNA hypothesis, first articulated by Salmena and colleagues in 2011, proposes that long non-coding RNAs can communicate with protein-coding messenger RNAs by competing for the same microRNA molecules. MicroRNAs are short RNA strands that normally bind to target messenger RNAs and silence them, so any RNA that binds and sequesters a microRNA effectively lifts the brake on that microRNA’s real targets. LINC00612 has previously been implicated in this kind of crosstalk in osteosarcoma, bladder cancer and colon adenocarcinoma, and a separate study linked a LINC00612/miR-31-5p axis to endothelial cell injury in cigarette smoke exposure. What the new work adds is the upstream driver: in this kidney cancer, the entire circuit appears to be switched on by the transcription factor TFEB itself.

Establishing that upstream connection required two complementary molecular techniques. Dual-luciferase reporter assays, in which the LINC00612 promoter is wired to a light-producing enzyme, showed that TFEB binding specifically activated the promoter, and chromatin immunoprecipitation experiments physically pulled down the promoter DNA along with TFEB protein, confirming that the transcription factor docks directly onto the LINC00612 regulatory region inside cells. In other words, TFEB is not merely correlated with LINC00612 expression; it is transcriptionally commanding it. Because the Alpha-TFEB fusion gene is the defining genetic lesion of this tumor subtype, the result provides a satisfying causal chain: the chromosome translocation creates the fusion, the fusion elevates TFEB activity, and TFEB turns up the volume on LINC00612.

With the top of the cascade established, the team tested what each link actually does to cancer cell behavior. When they overexpressed LINC00612 in ordinary HK-2 kidney cells, the cells became more proliferative, more migratory in wound healing assays and more invasive through membrane barriers, as measured by CCK-8 proliferation and transwell invasion assays. Conversely, when they knocked LINC00612 down in the fusion-positive HK-2-TFEB cells, those malignant capabilities were suppressed. The researchers also verified the middle and bottom of the relay: LINC00612 was shown to bind miR-31-5p directly, and miR-31-5p was shown to target CTNNB1. Reducing CTNNB1 expression likewise dampened the malignant functions of the cells, consistent with beta-catenin, a central player in the Wnt signaling pathway, being the downstream effector that ultimately drives the cancer phenotype.

Cell culture, however convincing, is only half the story, so the team turned to animal models to see whether the same axis governs tumor growth in living tissue. In mice, overexpression of either TFEB or LINC00612 promoted tumor growth, while overexpression of miR-31-5p inhibited it. The animal experiments, approved by the Animal Ethics Committee of Anhui Medical University, thus recapitulated the in vitro findings and demonstrated that manipulating any single node of the pathway, the transcription factor, the long non-coding RNA or the microRNA, is sufficient to change the trajectory of tumor growth in vivo. The consistency across molecular, cellular and animal levels gives the proposed TFEB/LINC00612/miR-31-5p/CTNNB1 axis unusual robustness for a study of such a rare malignancy.

The therapeutic implications are potentially significant. Because each component of the axis is a distinct molecular species, the pathway offers several points of attack. Antisense oligonucleotides or small interfering RNAs could theoretically silence LINC00612, microRNA mimics could restore miR-31-5p levels, and agents already in development against Wnt/beta-catenin signaling could blunt the downstream effect of CTNNB1. Notably, miR-31-5p has previously been described as a tumor suppressor in renal cell carcinoma through its targeting of cyclin-dependent kinase 1, which fits neatly with the new finding that its depletion by LINC00612 removes a brake on tumor progression. Prior work from the same group had also shown that the Alpha gene upregulates TFEB and promotes malignant transformation, making the present study a natural extension of a decade-long investigation into this fusion-driven cancer.

The study also contributes to a broader shift in cancer biology. Long non-coding RNAs, once dismissed as transcriptional noise, are increasingly recognized as master regulators of tumor behavior, and ceRNA networks have now been documented in hepatocellular carcinoma, gastric cancer, cervical cancer, prostate cancer and clear cell renal cell carcinoma, among others. By tying a specific lncRNA to a defining chromosomal translocation, the Anhui team has shown how a structural genetic lesion can be translated, through non-coding RNA circuitry, into the everyday business of cancer cell proliferation and spread. That perspective may also help explain why some t(6;11) tumors behave aggressively while others do not: variation in the activity of the LINC00612/miR-31-5p module could modulate the malignant potential that the fusion gene confers.

Caveats remain, as they always do at this stage of translation. The work rests on engineered cell lines and mouse models rather than large panels of patient tumors, and the rarity of t(6;11) renal cell carcinoma means that validating the axis in clinical specimens will require multi-institution collaboration. Whether blocking LINC00612 in patients is feasible and safe is unknown, and microRNA-based therapies have historically faced delivery challenges. Nevertheless, the identification of a complete, experimentally verified signaling relay, from the Alpha-TFEB fusion gene through LINC00612 and miR-31-5p to CTNNB1, gives researchers a concrete molecular target where previously there was only a correlation. For patients with this rare kidney cancer, whose treatment options have been limited by the tumor’s resistance to conventional therapies, the study offers something precious: a map of the enemy’s command structure, drawn molecule by molecule, and several new places to strike.

Subject of Research: The TFEB/LINC00612/miR-31-5p/CTNNB1 signaling axis in t(6;11) translocation renal cell carcinoma progression

Article Title: TFEB promotes the progression of t(6; 11) translocation renal cell carcinoma by upregulating LINC00612 expression

Article References: Ni, H.-Y., Zhang, X.-X., Wang, X.-R., Ma, J., Yu, X.-J., & Zhan, H.-Q. (2026). TFEB promotes the progression of t(6; 11) translocation renal cell carcinoma by upregulating LINC00612 expression. Medical Oncology, 43(11), Article 304. https://doi.org/10.1007/s12032-026-03411-6

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03411-6

Keywords: TFEB, LINC00612, miR-31-5p, CTNNB1, t(6;11) translocation renal cell carcinoma, long non-coding RNA, ceRNA network, Alpha-TFEB fusion gene, renal cancer, Wnt signaling, tumor progression, Medical Oncology

The research, published in Supportive Care in Cancer, involved twelve adults with advanced bladder or renal cancer receiving immune checkpoint inhibitor therapy at a tertiary cancer centre in London. Through individual semi-structured interviews lasting between 34 and 69 minutes, the team led by Nicola Peat of Guy’s and St Thomas’ Hospital NHS Foundation Trust explored how patients perceive and experience physical activity during immunotherapy. The interviews were transcribed verbatim and analysed using Braun and Clarke’s six-phase thematic analysis, a rigorous framework for identifying patterns across qualitative data. Four main themes emerged: the purpose of physical activity participation, the factors that help or hinder it, the striking lack of support from healthcare professionals, and the kind of support patients actually want.

The scientific rationale for the study is compelling. Physical activity is known to mitigate many cancer treatment side-effects, including fatigue and anxiety, and is associated with improved physical function and health-related quality of life across cancer populations. More intriguingly, emerging evidence suggests exercise may exert immunomodulatory effects that contribute directly to tumour control. In preclinical research, moderate-intensity exercise has been shown to reduce tumour size by mobilising highly differentiated natural killer cells and increasing the infiltration of CD8-positive T cells into tumours, the very immune mechanisms that checkpoint inhibitors are designed to enhance. This has led researchers to propose that exercise may have both a conditioning effect and a tumour immune surveillance effect, potentially amplifying the benefits of immunotherapy itself.

Current guidelines recommend that adults with cancer engage in at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic exercise per week, plus two resistance-training sessions. Yet physical activity levels typically decline after a cancer diagnosis, with fewer than 30 percent of individuals meeting these recommendations. The new study reveals how this gap plays out in the lives of patients on immunotherapy. Most participants described a decline in activity following diagnosis, driven by frequent hospital visits, debilitating side-effects, and a simple lack of knowledge about what was safe or beneficial. Fatigue emerged as the dominant barrier, with one participant describing having absolutely no energy, and another attributing profound exhaustion to treatment-induced pituitary and thyroid dysfunction, telling researchers they were more worn out than during their army days.

Pain also limited movement, particularly where cancer had spread to bones in the hip and leg, while nausea, vomiting, skin rash and itchiness added further obstacles. Psychological factors mattered too. One participant described falling into a dark period after diagnosis, spending most days in bed with the blanket over their head, and reflected that help to snap out of it might have changed everything. Notably, the study identified barriers unique to checkpoint inhibitor therapy: endocrine-related fatigue, nausea and skin symptoms that fluctuate across treatment cycles, creating a moving target for both patients and anyone prescribing exercise. Social support cut both ways, with some patients encouraged by family members to walk to the shops, and others told by worried relatives to cancel gym memberships and rest.

Against these barriers, participants described powerful motivations. Physical activity represented independence, normalcy and control, a way of living life on their own terms. Walking was the most common activity, woven into daily routines such as commuting, shopping and playing with grandchildren. Immunotherapy itself acted as a beacon of hope, with one patient describing the treatment as a last chance of survival and a reason to be as fit and well as possible. Participants also credited exercise with lifting mood, managing comorbidities such as pre-diabetes, and easing fatigue and pain, with one describing how supervised treadmill sessions at the cancer centre gym restored the ability to walk at a good pace and take grandchildren to the park. Several described physical activity as their therapy place, a source of routine, sanctuary and a happiness factor.

The most striking finding, however, was the silence of the clinical team. Every participant reported receiving little or no physical activity advice during routine appointments. Some recalled only vague encouragement to keep doing what they were doing, while the majority received nothing at all. When asked whether advice would have helped, all but one said yes, with one patient noting that information about exercise would totally have changed the way they felt about it. Several said that simply reading the study information sheet sparked a desire to become more active, and argued that such information should be given to patients at the start of treatment. Participants perceived that clinicians prioritised drug-based management of side-effects over conversations about movement, and physiotherapy referrals, when they occurred, focused on managing impairments rather than broader activity benefits.

What patients want, the study found, is structured, personalised and expert-led support rather than leaflets or generic exhortations. They wanted someone to show them the right exercises for their specific tumour sites and limitations, trusted professionals with knowledge of both cancer and exercise, clear targets and progress tracking, and flexible programmes that accommodate the good and bad days of treatment cycles. Walking and strength training were the most favoured activities, followed by cycling and swimming, and participants favoured hybrid models combining supervised hospital or gym sessions with home-based activity. Crucially, they endorsed a periodised, auto-regulated approach, doing less during treatment weeks and more in the weeks after, an approach consistent with research showing that chemotherapy-periodised exercise improves adherence and symptom management compared with linear progression.

The authors argue that structured physical activity is a promising but underutilised strategy for managing cancer and treatment-related side-effects during checkpoint inhibitor therapy, and that these patients have distinct needs requiring personalised support. Their recommendations include embedding professionals with cancer-specific exercise expertise, such as physiotherapists, directly into cancer clinics and care pathways, improving referral routes to rehabilitation specialists, and training healthcare professionals to close knowledge and confidence gaps. Prior research suggests only between 6 and 44 percent of cancer patients receive physical activity information during oncology appointments, and this study suggests immunotherapy patients are no exception. Given exercise’s potential to enhance both quality of life and possibly immunotherapy response, the researchers call for future studies to evaluate which checkpoint inhibitor side-effects can be mitigated through activity, and to test accessible, scalable interventions across patient groups.

The study has limitations. Recruitment came from a single UK tertiary centre with a relatively homogeneous group of bladder and renal cancer patients, all receiving checkpoint inhibitors, which may limit generalisability to broader populations or other treatments. The supportive context of the specialist unit and good transport links may also have under-represented socioeconomic and environmental barriers reported elsewhere. Nevertheless, the methodology was rigorous, reported against the COREQ checklist, with ethical approval, member-checked transcripts and reflexive analysis. For patients whose treatment is their last hope of survival, the message from this research is clear: they want to move, they believe movement helps, and the healthcare system needs to start telling them how.

Subject of Research: Patient perspectives and experiences of physical activity during immune checkpoint inhibitor treatment for advanced urological cancers

Article Title: Physical activity in advanced urological cancers undergoing immune checkpoint inhibitor treatment: a qualitative study exploring patient perspectives and experiences

Article References: Peat, N., Jones, G. D., Veal, I., Kinsella, N., Karagiannis, S. N., & Van Hemelrijck, M. (2026). Physical activity in advanced urological cancers undergoing immune checkpoint inhibitor treatment: a qualitative study exploring patient perspectives and experiences. Supportive Care in Cancer, 34(10), Article 963. https://doi.org/10.1007/s00520-026-11195-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11195-8

Keywords: physical activity, immune checkpoint inhibitors, immunotherapy, bladder cancer, renal cancer, urological cancer, qualitative research, exercise oncology, cancer rehabilitation, fatigue, supportive care, patient perspectives